Prostate cancer (CaP) is the most common cancer in adult men in North America. Since there is no naturally occurring prostate cancer in the mouse, preclinical studies stipulate for the establishment of a genetically manipulated mouse CaP model with features close to the human situation. In view of the limitations of transgenic technique-derived CaP models, herein we report the first application of knockin technology to establish a new mouse adenocarcinoma prostate model (PSP-KIMAP) by targeting of SV40 Tag to a prostate tissue-specific gene, PSP94 (prostate secretory protein of 94 amino acids). In order to demonstrate its novelty, we compared KIMAP to a PSP94 gene-directed transgenic mouse adenocarcinoma of the prostate (PSP-TGMAP) model. The CaP development of the PSP-KIMAP mice started almost immediately after puberty at 10 weeks of age from mouse prostatic intraepithelial neoplasia (mPIN) with microinvasion to well-differentiated CaP, and demonstrated a close-to-human kinetics of prolonged tumor growth and a predominance of well and moderately differentiated tumors. The invasive nature of KIMAP model was demonstrated by multitissue metastases (lymph node, lung and liver etc) and also by immunohistochemical study of multiple invasive prostate tumor markers. PSP-KIMAP model is responsive to androgen deprivation (castration). The knockin technology in our KIMAP model demonstrates highly predictive CaP development procedures and many advantageous features, which the traditional transgenic technique-derived CaP models could not reach for both basic and clinical studies. These features include the high stability of both phenotype and genotype, highly synchronous prostate cancer development, high and precise prostate tissue targeting and with no founder line variation. The differences between the two CaP models were attributed to the introduction of a single endogenous knockin mutation, resulting in a CaP model self-regulated and controlled by a prostate gene promoter/enhancer of PSP94.
Introduction
Mice and other rodents do not spontaneously develop prostate cancer. For this reason, the development of genetically engineered (GE) mouse prostate cancer (CaP) models is critical for preclinical studies of CaP, the most common cancer in adult males in North America. Animal models that mimic genetic alterations and clinical courses of human prostate cancer are at high demand for the study of the molecular mechanisms underlying prostate tumorigenesis and progression, and for innovation and validation of new anticancer strategies.
Transgenic technique was first applied through the utilization of identified promoter elements that direct specific transgenic expression to the prostate (Spence et al., 1989; Maroulakou et al., 1994; Greenberg et al., 1995; Gingrich et al., 1996; Thompson, 1996; Cleutjens et al., 1997; Perez-Stable et al., 1997; Wei et al., 1997; Garabedian et al., 1998; DiGiovanni et al., 2000; Watabe et al., 2002) . Several mouse models of prostate cancer were developed, including the prostate organ reconstitute model (for a review, see Green et al., 1998; Huss et al., 2001; Matusik et al., 2001; Abate-Shen and Shen, 2002) . Overexpressing transgenic lines derived from regulatory elements includes: the rat prostate steroid-binding protein (PSBP or C3(1)) Maroulakou et al., 1994 , the human prostate-specific antigen (PSA) (Cleutjens et al., 1997; Wei et al., 1997) , the human fatal G-globin/SV40Tag (Perez-Stable et al., 1997), Cryptdin-2 (CR-2)/SV40 Tag (Garabedian et al., 1998) , bovine keratin 5 (BK5) promoter/insulin growth factor 1 (DiGiovanni et al., 2000), prostate stem cell antigen (PSCA) (Watabe et al., 2002) and an osteocalcin-based cotargeting vector (Matsubara et al., 2001) . Rat probasin gene-based transgenic adenocarcinoma prostate (TRAMP) (Greenberg et al., 1995) and LPB-SV40 tag (LADY) ) models are currently the most prevalently used murine prostate cancer models. Both demonstrated salient characteristics of human CaP, progressing from prostatic intraepithelial neoplasia (mPIN) to CaP by 12 weeks, then to highly invasive prostate cancer and mimicking androgen response and refractory diseases. However, these models differ from human prostate cancer in several key respects: their rapid rate of disease progression; the prevalence of neuroendocrine tumors; the absence of a zonal-differentiated distribution in human prostate cancer grading; the lack of the preferential route of lymph node-bone metastasis of human prostate cancer through the lymph nodes (for reviews, see Huss et al., 2001; Abate-Shen and Shen, 2002) .
Until recently, all aforementioned transgenic mouse prostate cancer models seemingly have been underutilized. This may be at least due to the transgenic technique utilized, since the transgenic technique is very empirical, being affected by other factors of insertion sites, length and copy numbers of transgene DNA, variations among breeding lines and instability of genotype and phenotype.
In view of the limitations of the transgenic technique, alternative models have been sought, utilizing knockout technique and newly discovered genes. A number of knockout mice with a tumor suppressor gene PTEN/ Mmac1 were generated. Invariably, the resultant homozygous mutant generated were fatal in early embryonic development, and in the heterozygous form, mice developed neoplasia in multiple organ systems (breast and prostate) (Podsypanina et al., 1999; Di Cristofano et al., 2001) . Mice lacking Mxi1 (belonging to Myc oncoprotein) exhibited progressive, multisystem (kidney, spleen, prostate) abnormalities, and had increased susceptibility to tumorigenesis with the cancer-prone phenotype (Schreiber-Agus et al., 1998) . A homeobox gene Pax-2 is considered important in the regulation of the reproductive system development, and the Pax-2 knockout mouse showed absence of kidneys, ureters and the genital tracts including the seminal vesicles, although the prostate was normal (Miyamoto et al., 1997) . Mice deficient in another homeobox gene, such as Nkx3.1 (Kim et al., 2002) , developed prostatic intraepithelial neoplasia (PIN)-like lesions resembling human PIN (Kim et al., 2002) . However, as with all experimental loss-of-function mice, the knockout mouse prostate cancer models established so far have rarely developed prostate carcinoma (for a review, see Huss et al., 2001; Abate-Shen and Shen, 2002) .
PSP94, also known as b-microseminoprotein (Abrahamsson et al., 1988; Hara and Kimura, 1989; Hyakutake et al., 1993) is one of the three most abundant secretory proteins from the prostate gland (the others being PAP: prostatic acid phosphatase and PSA (Dube et al., 1987; Abrahamsson et al., 1988) , and is generally considered to be a prostate-tissue-specific protein (for a review, see Hara and Kimura, 1989) . As with PSA, PSP94 is under androgen regulation and is typically responsive to androgen deprivation. Studies in human, primate, pig, and rodent PSP94 have showed that PSP94 is a conserved, but also a rapidly evolving protein (for a mini-review, see Fernland et al., 1996; Xuan et al., 1999; Lazure et al., 2001) . We have previously established a model involving a PSP94 (prostatic secretory protein of 94 amino acids) gene promoter/enhancer region-directed transgenic mouse adenocarcinoma in the prostate (PSP-TGMAP), which exhibits the features of highly precise prostatetissue-specific targeting (Gabril et al., 2002) . Both fast growing (TG183, similar to the TRAMP model) and slow growing (TG186-B and -C lines, similar to the LADY model) breeding lines were established. However, those breeding lines demonstrated nonsynchronous CaP growth, very high phenotypic fluctuations in tumorigenesis and tumor progression, and genotypic instabilities in different breeding lines. In this study, we report by using gene targeting technique, the establishment of the first knockin (at PSP94 gene, process found in Figure 1 ) mouse adenocarcinoma of the prostate model (PSP-KIMAP). We critically appraised and compared two CaP mouse models (TGMAP and KIMAP) by the PSP94 gene and demonstrated that the PSP-KIMAP model possesses important advantages over the traditional transgenic technique-derived murine CaP model for studying the molecular biology and therapy of the prostate cancer.
Results
Comparison of PSP94-KIMAP and -TGMAP models: KIMAP mice demonstrated rapid SV40 Tag derived tumorigenesis and a close-to-human kinetics of the prostate tumor developments Development of CaP in KIMAP mice proceeded through a series of defined stages, including mPIN with microinvasion, prostate cancer in situ, invasive and metastatic cancer (process shown in Figures 2 and 3) . According to the standard of histological classification for mouse transgenic CaP models as TRAMP, LADY and C(3) models (Maroulakou et al., 1994; Greenberg et al., 1995; Gingrich et al., 1996; Shibata et al., 1996; Deshmukh and Foster, 1998; Masumori et al., 2001; Mostofi et al., 2002) and our previous report (Gabril et al., 2002) , percentages (% of mice analysed) of categories of cancer (CaP, Figure 3a ), well and moderately differentiated CaP (WD þ MDCaP, Figure 3b ), poorly differentiated CaP (PDCaP, Figure 3c ) and mPINs (including high-grade mPIN with microinvasion, Figure 3d ) were analysed. KIMAP mice (n ¼ 169) were first characterized for the correlation of tumorigenesis and CaP development with age of 7-91 weeks, with numbers (n>10) of mice in each age groups analysed were evenly distributed (Figure 3a-d) . Figure 3d shows that all KIMAP mice developed mPIN immediately after puberty. mPIN with microinvasion started (6-7 weeks of age) with a high rate of 69.9% (51/73). Well-differentiated CaP was detected from 10 weeks of age in KIMAP mice, and demonstrated ( Figure 3b ) a steadily prolonged cancer development in KIMAP mice correlated with age (Po0.0001). PSP-TGMAP (n ¼ 187) showed rapid cancer development in the late age groups found in both fast-(TG183-A, Po0.001) and slow-CaP growing breeding lines (TG186-B and -C, Po0.0001) (Gabril et al., 2002) .
The majority of CaP (overall 87/96) in KIMAP were well and moderately differentiated CaP in almost all age groups (Figure 3b) , whereas, in PSP-TGMAP there was a pulse-like, low incidence ( Figure 3b ) starting from 24 weeks of age, which suggests an aggressive, fast growing tumor development in contrast to KIMAP. The overall incidence of carcinoma in PSP-TGMAP breeding line TG183 was 33% (32/97), which was distributed throughout all age groups (mostly within 6 months, Figure 3a- Starting from age of 52 weeks, all mice (n ¼ 12, Figure  3a -c) synchronously developed visible cancer, which appeared in microdissection as enlarged glands in both dorsolateral and ventral prostate lobes. CaP incidence in AP (coagulation gland) was rare. No difference of tumor heterogeneity and tumor extent was found in either CD1, C57BL6 or 129Sv genetic backgrounds (data not shown). Characterization of the invasive and metastatic nature of KIMAP model By age of 60 weeks, pelvic lymph nodes were appearing as visible, enlarged glands in most (6/7) of KIMAP mice dissected. By age of 70 weeks and over, metastases to outside prostate organ to liver (n ¼ 8, 8/17) and lung (n ¼ 5, 5/19) tissues were found in several KIMAP mice. As a control, in 1 year time, no primary liver and lung tumors (caused by nonprostate targeting (NPT) of SV40 Tag gene) were identified in KIMAP mice (n>252). and PSP94 protein ( Figure 4k ) demonstrated their prostate origin. As with the highly metastatic TGMAP model (Gabril et al., 2002) , the IHC signal of SV40 Tag in those liver and lung metastatic tissues in KIMAP mice was weak and less homogenous. Only small portion of metastasized tumor cells showed positive, light nuclear staining. The majority of lung tumor area were weaker stained for PSP94 antibody, possibly because poorly differentiated cancer cells lost prostate cell specific-elements to support the transgenic expression driven by the PSP94 gene promoter, demonstrating a trend of androgen-independent CaP development of KIMAP at this stage.
Further characterization of the responsiveness nature to androgen-deprivation and the invasive nature of carcinoma in KIMAP mice by IHC staining of tumor associated markers
In order to demonstrate KIMAP model is responsive to androgen deprivation therapy in clinical trials, castration tests on KIMAP mice groups (n ¼ 5) were performed. As shown in Figure (Figure 4b ) of the AR demonstrates the prostate origin. Since most of SV40 Tag-derived transgenic CaP models demonstrated the invasive CaP development, we studied the qualitative correlation study of the oncogene expression with histological grades. As shown by IHC staining in Figure 5a and b, there is an apparently increased expression of SV40 Tag protein from high-grades mPIN to higher histological grades of adenocarcinoma. By a semiquantitative assay on the intensity and extent of IHC staining signals of SV40 Tag in 169 KIMAP mice, a significant correlation was established and demonstrated (data not shown). Next, expression of p53, a tumor suppressor gene closely associated with SV40 Tag oncogene protein in the nuclei, was parallelly analysed by IHC. The same correlation of p53 expression/accumulation in nuclei as the SV40 Tag in KIMAP mice of different histological grades, was also identified. The intensity and extent of IHC staining of p53 expression as shown in Figure 5c and d for KIMAP mice increased significantly from Knockin mouse prostate cancer model W Duan et al high-grade mPIN to poorly differentiated CaP. Nuclear staining with another cell proliferation marker (PCNA) showed more extensive and intensified expression in higher grade CaP (Figure 5f ) than in high-grade mPIN (Figure 5e ), while normal gland is negative (Figure 5e ). Finally, an antibody against a6b4 integrin, a downregulation invasive cancer marker, was tested for the loss of expression in KIMAP mice. Figure 5g showed strong staining of a6b4 integrin in the basal cells around the gland in the normal mouse prostate, while completely negative staining was found in high grade CaP in KIMAP mice (Figure 5h ).
The novelty and advantages of knockin techniques over the traditional transgenic technology A comparative study was conducted between the two PSP94 promoter/ enhancer region-directed murine CaP models established by utilization of the knockin (PSP94-KIMAP) and the traditional transgenic (PSP-TGMAP; Gabril et al., 2002) technologies.
(1) High genotypic and phenotypic stability in PSP-KIMAP mice: Traditionally in transgenic mouse models, genotype and phenotype stability was established by testing and screening for several breeding procedures, because transgenic technique could not repeatedly control the integrating sites and copy numbers on the mouse genome for each microinjection. We tested the stability of KIMAP model by assessment of the copy number (gene targeting insertion at PSP94 locus (Gabril et al., 2002) , Figure 1b , d), rate of CaP incidence and tumor development in at least three breeding generations in both PSP-TGMAP and KIMAP mice ( Figure 6a ). As demonstrated by Southern blotting experiments (Gabril et al., 2002) , the instability of transgene copy numbers in the chromosome also correlated with NPT (Non-prostate targeting) in terms of SV40 Tag expression, which resulted in an increased tumor incidence in other tissues (bone, liver, skin, etc.) instead of the prostate tissue ( Figure 7d ). As shown in Figure 6b , the rate of NPT in the three lines (TG183-A, TG186-B, TG186-C) in three breeding generations (F1, F2, and F3) was 3.5% in F3 of A line, 1.3 and 2.6% in F2 and F3 of B line respectively; and 24, 12 and 4.1% in F1, F2 and F3 of C line respectively. Figure 6b also shows the correlation of the high copy number of 186 transgenic DNA in the mouse genome with the incidence of the NPT (Po0.0001). Figure 7a shows that the knockin genotype remained stable for targeting at the PSP94 gene. Figure 8a shows that three generations (F1-F3) of KIMAP mice followed the same tumor development pattern. This phenotypic stability was also maintained in other strains CD1, C57BL6 and 129Sv (data not shown). Whereas in TGMAP, the 186-C line showed decreasing transgene copy numbers from F 0 (extraordinarily high) to F 3 during the breeding process (Gabril et al., 2002) (Figure 6b ).
(2) High prostate-tissue-specific targeting rate in PSP-KIMAP model: Precise prostate-tissue-specific tumor induction is an important standard for mouse CaP modeling, since it will be critical in determining the prostate cancer metastasis route. Owing to uncontrolled integration and copy number effects of transgenes, NPT is a common side effect associated with transgenic mouse models. We reported previously that two of three PSP-TGMAP breeding lines demonstrated precise prostate targeting inducing cancerous changes (Gabril et al., 2002) . We have monitored the progress of four TGMAP breeding lines 183 (a and d) and 186 (b and c) for 2 years. Although the NPT rate is still low at an incidence of 4% (31/740), all subsequent generations showed NPT (Figure 7) . The NPT tissues by gross pathology mostly were founded in liver, bone and skin (Figure 7) . Tumor growth in these nonprostate locations was usually rapid and often fatal. The KIMAP mice (n>252) were monitored for up till 94 weeks and no NPT was observed (Figures 3 and 4) .
(3) No-variations in all founder lines in PSP-KIMAP model: Empirically, every transgenic mouse model must be tested and screened for several founder lines, due to high fluctuations in both phenotype and genotype in between founder lines. The founder line of knockin mice was designed in this study as a fertile germline of mice with a transmittable mutant genotype. Most of the mutant phenotypes were tested in breeding progenies with a CD1 background, while in C57BL6 and 129Sv strain background, no strain variation was identified (data not shown). As shown in Figure 8a , six breeding founder lines of KIMAP were tested and all showed a similar tumor development. In the process of KIMAP mouse breeding, along with their three generations of progenies, no variation (P>0.05) of tumor development or growth rate among various families was observed and separated. As a comparison, four PSP-TGMAP founder lines (two 183, and two 186 lines) were plotted ( Figure 8b ) in terms of tumor development at two age groups (which normally tumor developed). Variations of founder breeding lines were found to be significant (Po0.01): two transgenic breeding lines of 183 (TG183-A, TG183-D) showed the two extreme tumor development rates (fastest and slowest), while the two 186 founder lines (TG186-B, TG186-C) showed very different tumor development (Figure 8b ), as well as very different stabilities of both phenotype and genotype (Figure 8b ).
(4) Highly synchronous prostate growth in KIMAP mice: Stochastic and asynchronous incidences of CaP have been reported in several transgenic models (Maroulakou et al., 1994; Gingrich et al., 1996) and confirmed in our TGMAP model (Gabril et al., 2002) . Prostate cancer in KIMAP model developed immediately after puberty (Figure 3 ). Almost 100% of KIMAP mice developed well differentiated CaP from 10 to 12 weeks of age, showing higher CaP incidence than TGMAP. Figure 3 also demonstrated that CaP incidences in PSP-KIMAP mice were more synchronous than TGMAP, (1) higher rates of CaP incidence in KIMAP (96/169, 56.8%, Figure 3 ) than in TGMAP (44/ 187, i.e. approximately 23.5%, distributed in almost all age groups), Po0.0001 (by w 2 test); (2) lower rates of mPIN incidence in KIMAP (73/169, 43.2%) than TGMAP (143/187, 76.5%) mice, which were dispersed among all age groups (Figure 3d ), Po0.0001 (w 2 test); (3) earlier and higher occurrence of mPIN with microinvasion in KIMAP (Figure 3d ) (30.2%, 51/169 of total mice tested) than TGMAP mice (1%, 2/187 of total mice tested), Po0.0001; and (4) only in KIMAP mice, mPIN ( Figure 3d ) and poorly differentiated CaP (Figure 3c ) were found at the early and late (>52 weeks) age groups separately (for a summary see Table 1 ). The prolonged CaP development with well to moderately differentiated CaP maintained very synchronously in almost 1 year. Starting from the age of 52 weeks, all mice (n>12) synchronously developed visible similar sized cancer, appearing in microdissection as enlarged glands in the dorsolateral and ventral prostate lobes. This highly synchronous and predictive feature was observed with either CD1, C57BL6 or 129 Sv genetic backgrounds. Figure 8a also shows the synchronous CaP developments in different founder lines (F 0 germ breeding lines) as well.
Discussion
We created a new murine CaP model by taking advantage of knockin biotechnology, which at the present time is becoming a conventional technology, which demonstrated several advantageous features over the traditional transgenic technology. As summarized in Table 1 , PSP-KIMAP model is a highly predictable model as compared with the PSP-TGMAP model. Although tumorigenesis is a stochastic event inside the acini of the gland, statistically a significant majority of KIMAP mice undergo steady cancer growth after puberty (Figure 3b, d) . The CaP in KIMAP mice shows some desirable experimental features, such as: (1) early incipient CaP development (very synchronously starting from 8 to 12 weeks age) immediately after puberty, due to the utilization of a strong prostate-tissue-specific promoter. KIMAP showed higher heterogeneity and tumor penetrate over the prostate gland than the PSP-TGMAP mice (data not shown, manuscript in preparation). The PSP94 gene promoter is a strong, prostatetissue-specific promoter, and the SV40 Tag is coupled with the full capacity of a promoter of this most abundant prostate-tissue-specific secretory gene. (2) CaP progression in the KIMAP model demonstrated a closeto-human kinetics with the steady tumor growth and the dominant patterns of well and moderately differentiated adenocarcinoma. (3) KIMAP model revealed lower variation and higher stability of both phenotype and genotype in all breeding lines and in several mouse strains, as well as in progenies of several generations; furthermore CaP developments in DLP and VP lobes were equally distributed with no statistical difference (data not shown); (4) more selective prostate targeting with the lowest incidence of nonprostate tumor induction. PSP-KIMAP showed a lower level than PSP-TGMAP model for NPT. (5) As compared with transgenic technique, the KIMAP model is genetically easier to establish a stabilized homozygote strain, as it revealed standard Mendelian segregation in crossing with heterozygotes and remain a stable genotype in homozygotes. We have characterized that PSP-KIMAP mice are responsive to castration, as with the natural PSP94 gene expression as we reported (Imasato et al., 2001) .
In transgenic CaP models, there is a typical artifact of the forced manipulation of the promoter, which is driving a tumor inducer gene (see a summary of Table 1) . The transgenic CaP model shows the inheritability and reproducibility of many salient features of CaP in all progenies. However, it is still an empirical model for the following reasons: (1) The cis effects by insertion site(s) of transgenic DNA in the transgenic mouse genome are random, uncontrolled and unpredictable. (2) The copy number of transgene is also uncontrolled, and thus is less repeatable and is the cause of unstable genotype and phenotype. (3) In most transgenic experiments, it is almost impossible to determine if a transgene DNA contains sufficient functions to be tested. We may assume that other trans factors may be located further upstream, since there have been reports of a regulator element located remote (>100 kb) from the structural gene (Pham et al., 1996) . (4) Another nonrepeatable factor in the transgenic technique is the breeding and selection procedure required to attain more stable mouse lines, which further jeopardizes the reliability of the experimental model. Intuitively, it is assumed that for any transgenic experiment, the critical factor for success is to establish enough founder lines, due to the huge variation in the genotype or phenotype in different breeding founder lines. No regulatory factors/regions (cis, trans, including introns) is affected by knockin technology. The PSP94 gene promoter is a strong, prostate tissue-specific promoter, and the SV40 Tag is coupled with the full capacity of a promoter of this most abundant prostatetissue-specific secretory gene. (5) As compared with transgenic technique, the KIMAP model is genetically easier to establish a stabilized homozygote strain, as it revealed standard Mendelian segregation in crossing with heterozygotes and remain a stable genotype in homozygotes.
A mouse model autochthonously mimicking human CaP must demonstrate the following features that are characteristic of human CaP: correlation with increasing age; high incidence rate; slow and synchronous CaP Knockin mouse prostate cancer model W Duan et al growth rate; a histological CaP structure of a majority of well to moderately differentiation; androgen dependence, and initial responsiveness to hormone therapy followed by the development of refractoriness to androgen ablation therapy, and high propensity for bone metastasis. The first important characteristic of the kinetics of human CaP development is the protracted tumor growth rate and the highly regulated CaP growth, which started as earlier as 20 s of PIN, till the sixth decade or later for clinically detectable CaP. It is because of the human CaP specific-kinetics that determines the basis of one of the clinical treatment strategy, that is, watchful Figure 6 Comparison of genomic and phenotypic stabilities in breeding lines in KIMAP and TGMAP mice: (a) In KIMAP mice, histological grades were compared by percentages in total mice tested for three breeding generations (F1, F2, F3, n ¼ 9, 24, 4 separately) in the same age groups of 20-27 weeks respectively. (b) Comparison of NPT-induced cancer incidence (% of total mice tested) in tissues other than the prostate in three TGMAP mice breeding lines TG183-A, TG186-B, TG186-C. A correlation of high copy (HC, shown in black bars) of transgene 186 with NPT (gray bars) was demonstrated. Numbers are the incidence of HC and NPT/total of mice tested. Comparison: Only two age groups mice were tested, as they represented the age groups with the most frequent tumor incidence Figure 7 Prostate targeting of SV40 Tag-induced tumorigenesis and developments in KIMAP and TGMAP mice. The rate of NPT incidence (in both male and female) was indicated as percentage of mice (n ¼ total numbers tested) showing prostate cancer only, that is, prostate targeting mice as 100%. Numbers listed for each bar are mice numbers detected with NPT. In order to better compare four graphs, bar breaks were shown beyond the limit of the graph. Numbers refer the numbers of NPT mice. Sal. gld: Salivary gland; adrenal gld: Adrenal gland; Renal LN: Renal lymph node waiting, since the majority of men in the United States who are diagnosed with prostate cancer are at low to intermediate risk for disease-specific mortality. PSP-KIMAP model effectively mimics the human CaP in this regard, through the introduction of a single endogenous knockin mutation resulted in a model with a self-regulated and highly controlled CaP growth rate, which is clinically relevant. The fast, uncontrolled and close to exponential tumor growth in late stage of puberty (tumor weight could reach 15 g for a 35 g body weight) is the highly characteristic in either of the fast PSP-TGMAP (as with our 183-A breeding line) or slow TGMAP breeding lines (as with our 186-B and -C). The simplest theoretical explanation is that none of these two breeding lines is fully regulatable as a result of an endogenous mutation by a prostate-specific gene (detailed summary, see Table 1 ). No regulatory factors/ regions (cis, trans, including introns) is affected by knockin technology. The PSP94 gene promoter is a strong, prostate tissue-specific promoter, and the SV40 Tag is coupled with the full capacity of a promoter of this most abundant prostate tissue-specific secretory gene. We have observed PSP94 downregulation (suppression) by immunohistochemistry shortly after puberty in heterozygous PSP-KIMAP mice while SV40 expression was initiated, and this suppression was maintained at a low, but not completely shutting down level, by the PSP94 promoter/enhancer (data not shown). The SV40 Tag-induced tumorigenesis started after puberty of the prostate gland along with the secretion of PSP94 protein, and the incipient CaP was as early as 12 weeks of age, which is almost the same as the TRAMP model (Greenberg et al., 1995; Gingrich et al., 1996) . The SV40 Tag expression in KIMAP mice is in turn under control by the prostate, since when normal prostate function is disturbed by tumor growth, SV40 Tag oncogene expression will be suppressed by PSP94 promoter/enhancer region. We reported this apparent suppressive mechanism of PSP94 in human prostate cancer biopsy samples (Imasato et al., 2000 (Imasato et al., , 2001 and this suppression/down regulation also observed with another abundant secretory protein of PSA (Stege et al., 2000) . It is the balance of positive (tumorigenesis) and negative (the suppression) regulatory effects to the SV40 Tag structural gene that enables the tumor to remain stable for most of the postpuberty period.
PSP94 promoter possesses potential to be regulated for epithelial-specific tumor progression, on the ground of reports (Oettgen et al., 1999; Kas et al., 2000) for several binding/reacting/regulation sites by epithelialrestricted ESE (epithelial-specific Ets) factors, a distinct set of transcriptional regulators governing epithelial cell differentiation. Approximately 85% of cancers (carcinomas and adenomas) originate as a result of aberrant gene expression in mainly glandular epithelial tissues, leading to defects in epithelial cell differentiation and proliferation, which is regulated by specific combinations of growth factors, hormones, adhesion molecules. Only a few epithelial cell-restricted transcriptional regulators have been characterized. Several binding sites by Ets 2 (Oettgen et al., 1999) and Ets 3 (Kas et al., 2000) factors in PSP94 promoter have been demonstrated to be prostate tissue-specific. We expect binding of Ets factors in PSP94 promoter/enhancer region in KIMAP mice may be prime reasons accounting for majority of epithelial tumors.
The second important characteristic of CaP modeling is the tumor progression from in situ adenocarcinoma to distant invasive adenocarcinoma. PSP-KIMAP mice demonstrated a process of the transition from in situ adenocarcinoma to invasive adenocarcinoma, which appeared at a late stage of 50-60 weeks of age and showed majority of lymph node metastases. After 1 year (>70 weeks), multifoci liver and lung tissue metastasize from the prostate cancer appeared as the major cause of Mouse prostate has been demonstrated very sensitive to SV40 Tag oncogene by all SV40 tag transgenic experiments. In our experiment, we found no differences of KIMAP phenotypic sensitivity in either breeding with CD1, C57BL6 or 129 Sv background. Prostate tissues from KIMAP mice were characterized by correlation studies with histological grades for the expression SV40 Tag oncogene and its binding tumor suppressor gene p53, by correlation with a number of tumor associated growth factors and integrins. Mice in the SV40 Tagderived KIMAP model showed (Figure 3d ) mPIN and microinvasion with earlier occurrence and a higher incidence than TGMAP mice, also with small acinar infiltration and foci of raggedly infiltrations to stroma. A semiquantitative test in different ages of KIMAP mice demonstrated the total invasive level increased significantly and correlated with histological grades (Po0.0001, data not shown). The invasive CaP in KIMAP mice was also characterized by loss of tumor associated integrins (a6b4) in the basal cells of tumor glands.
The third important characteristic of mouse CaP modeling is the studies on neuroendocrine (NE) carcinoma, since NE carcinoma may account for the development of the androgen ablation refractory prostate cancer. KIMAP mice demonstrated that the neuroendocrine carcinoma is not the major feature in KIMAP mice (by cDNA microarray assay, details see supplementary material in the web); only in a few mice at later stage (70-90 weeks of age) revealed the retardant NE differentiation (see supplementary data).
It is interesting that transmittance of the PSP-KIMAP mutant introduced by gene targeting in embryonic stem cell culture was through female chimeras. Since the primary biological function of PSP94 is still unknown, we may postulate that the original function of PSP94 is related to male fertility. PSP94 was hypothesized as a prostatic inhibin protein (PIP) to b-FSH (Follicle stimulation hormone) (Lokeshwar et al., 1993; Shukeir et al., 2003) , although this hypothesis is highly contentious (for a mini-review, see Xuan et al., 1999; Lazure et al., 2001) . In the present experiment on the knockout of PSP94 function, we observed no support for the 'PIP' theory: (1) We observed a close correlation with SV40 Tag expression with tumorigenesis and progression; (2) In either TGMAP or KIMAP mice, we observed suppression of PSP94 expression, which is the result of disrupting normal PSP94 secretion function by CaP as with all other secretory proteins from the prostate, but not vice versa; (3) We observed no significant differences in CaP development between homozygous and heterozygous KIMAP mice. No effect was observed on the fertility of homozygotes of KIMAP mice as in heterozygous and the same weaker expression of PSP94 expression was identified in homozygotes as well (data not shown). We can not exclude that the first intron (6 kb) of PSP94 gene may provide some promoter function in KIMAP mice. Further experiments are required to clarify the real biological function of PSP94, one of the most abundant protein from the human semen.
In conclusion, the new PSP-KIMAP model is different than all other SV40 Tag oncogene derived transgenic models due to the utilization of knockin technology. As with the goals of all GE prostate cancer models for human disease, the GE model which most closely mimics human CaP may reveal great similarities 
Materials and methods

Establishment of knockin mouse adenocarcinoma of the prostate (KIMAP) model
A targeting vector pPNTloxP was used to construct a PSP94 gene-targeting plasmid according to the strategy reported previously (Fong et al., 1995; Peng et al., 2000) . As shown in Figure 1a , the left and right arms for homologous crossing over are the 3.842 kb PSP94 promoter/enhancer region and part of exon 1 and the 5.5 kb intron 1 sequences (Xuan et al., 1999) . After double crossing over in the mouse genome in the 5 0 end of the PSP94 gene (Xuan et al., 1999) , the SV40 Tag (2.7 kb, both large T and small t antigens, a gift from Dr Janet Butel, Baylor College of Medicine) and the neomycin gene (1.9 kb) were inserted at the middle of the first exon (Kpn1 site) of the mouse PSP94 gene. The recombinant targeting vector DNA was introduced by electroporation into the embryonic stem (ES) cell line R1. Eight positive ES clones were screened and characterized from a number of G418-resistant individual clones by Southern blotting. The probe used for PSP94 gene targeting by Southern blotting experiments was a 500 bp (Stu1/Kpn1) located downstream from the right arm of the vector and was comprised of the complete exon 2 and the flanking intron area (Figure 1a) . Figure 1b illustrates the results of Southern blotting, showing the wild type (B12 kb) and mutant (B9 kb for knocked in) genomic fragments. Negative screening of GCV (ganciclovir) for TK (thymidine kinase) expression was also performed at the same time. Production of chimeras by aggregation with eight-cell embryonic cells of diploid CD1 strain and implantation into pseudopregnant female hosts was performed at the University of Toronto. From two positive ES clones with PSP94 gene targeting, 20 chimeras (11 male and nine female) with different fur coat colors were obtained. The chimeras were all tested for germline transmittability by breeding with CD1 and 129Sv strains, which were screened for germline progenies firstly for black coat color and by the PCR genotyping.
Establishment of transgenic mouse adenocarcinoma of the prostate (TGMAP) model
We followed our previously reported protocol (Gabril et al., 2002) with some modifications. In brief, two transgenic DNAs, TG183 (mouse PSP94 gene promoter/enhancer region directly targets the expression of a full-length SV40 Tag (T, t) transgene to the prostate) and TG186 (linking the PSP94 promoter/enhancer-exon1-part of intron 1 and exon 2 to the SV40 Tag gene within the same reading frame), were microinjected into the pronuclei of mouse strains CD1 and F1 hybrids of C57BL/6 Â CBA. These two transgenic breeding lines mimic the TRAMP and the LADY in terms of growth rate (fast and slow), tumorigenesis, responsiveness to androgen deprivation (castration) and the appearance of neuroendocrine carcinoma By PCR genotyping, several breeding lines were selected and established: two with transgene 183 and two with 186 (named B and C with low and high copies of transgene integrated in the chromosome; (Gabril et al., 2002) , according to the protocols as previously reported (Gabril et al., 2002) . In the past 2 years, approximately 600 male transgenic mice were analysed. The tumor induction rate, histological grade distribution, and the NPT rate were reviewed according to criteria previously reported (Gabril et al., 2002) .
PCR-genotyping, identification and breeding of transgenic and knockin mice by PCR and Southern blotting
All male chimeras were found to be partly fertile in breeding within the CD1 background. The majority of fertile males produced either no germlines, or the germlines proved not genetically transmittable to the progenies in breeding within either the CD1 or 129Sv background. Only two female chimeras produced knockin mice with mutation of the PSP94 gene transmittable to germlines. The founder line was designated as the germline mouse produced from chimeras mating with CD1 or 129Sv with full fertility and with a transmittable mutant genotype to the next generation. As germline transmittance through female chimeras is rare, some of the founder line mice and their breeding progenies (F1, F2, F3, either heterozygous or homozygous) were further characterized by Southern blotting experiments (Figure 1c) as well as by PCR genotyping (Figure 1d ). Primer pairs used for screening for germline progenies from chimeras by PCR genotyping were: Pr36-Pr16 for wild-type genome testing Pr36 5 0 GGC AAC AGC GTG TCA AAG 3 0 (promoter region near exon 1) and Pr16 5 0 CTA GCT CTG TCCAAG GA 3 0 (5 0 end of intron 1); Pr36-PrSVTag (5 0 CTA GCT CTG TCCAAG GA 3 0 , located at the 5 0 end of the SV40 Tag region). Transgenic (PSP-TGMAP) mice were identified by a quick PCR genotyping protocol as previously reported (Gabril et al., 2002) . Primer pairs used for TGMAP mice were Pr36-PrSVTag (for 183) and Pr70-PrSVTag (for transgene 186-B and -C lines) (Gabril et al., 2002) . TGMAP mice were further characterized by Southern blotting and copy numbers of 186 transgenic DNA in TGMAP were determined by a semiquantitative Southern blotting protocol as previously reported (Gabril et al., 2002) . By using SV40 Tag DNA fragment (2.7 kb) as a probe. Breeding of transgenic mice was all carried out in strains of CD1 or F1 hybrids (C57BL/6 Â CBA), first by mating with the wild type, then gradually by mating among transgenic mice.
Southern blotting: High molecular weight genomic DNA from R1 embryonic stem cell culture and mouse tail and liver was purified as previously reported (Fong et al., 1995; Peng et al., 2000) . Southern blots were prepared using B5 mg mouse tail chromosomal DNA for each lane digested by restriction enzyme and separated in a 0.5% agarose gel. For KIMAP mice, the probes utilized were the same as for ES cell colony.
Mouse anatomy, castration and testing of prostate targeting and NPT
The prostate along with the male accessory glands, that is, the ventral and dorsolateral prostate lobes (VP, DLP respectively), seminal vesicles (SV) and coagulation gland (CG, or AP, the anterior gland), were dissected out separately as per the description and definition reported (Imasato et al., 2001) . Surgical castration (orchidectomy) through scrotum route was performed under anesthesia as per previously reported (Gabril et al., 2002) . All animal experiments were conducted according to standard protocols approved by University Animal Care Committee. All organs and tissue samples (as indicated in the text) were subjected to gross pathological inspection, and any suspicious or abnormal looking tissue was sampled for immediate histological slide processing. In performing these procedures, NPT was defined as neoplastic changes (the maximum not beyond the mPIN) undetectable in the prostate, but detectable in non-prostate tissues (Gabril et al., 2002) .
